ICD-10-CM 2027 diagnosis code
T45.AX4DPoisoning by immune checkpoint inhibitors and immunostimulant drugs, undetermined, subsequent encounter
T45.AX4D is a valid, billable ICD-10-CM code for poisoning by immune checkpoint inhibitors and immunostimulant drugs, undetermined, subsequent encounter. It can be reported on claims for dates of service from October 1, 2026 – September 30, 2027.Short description: Poisn by immune chkpt inhibtr/immunostim drugs, undet, subs
Code last changed in FY2025 (effective October 1, 2024). Source: official FY2027 ICD-10-CM release from CDC/NCHS and CMS. Page updated September 29, 2026. About our data
About T45.AX4D
T45.AX4D is the ICD-10-CM diagnosis code for poisoning by immune checkpoint inhibitors and immunostimulant drugs, undetermined, subsequent encounter. It belongs to category T45 (poisoning by, adverse effect of and underdosing of primarily systemic and hematological agents, not elsewhere classified), block T36-T50 (poisoning by, adverse effects of and underdosing of drugs, medicaments and biological substances) and chapter 19 (injury, poisoning and certain other consequences of external causes). It is billable, so it can be reported on its own for dates of service from October 1, 2026 through September 30, 2027.
The 7th character "D" means subsequent encounter: use it for encounters after active treatment, while the patient is healing or recovering.
It is not a CC or MCC, so as a secondary diagnosis it doesn't change the MS-DRG severity level.
In MS-DRG v44.0, it is part of the grouping logic for DRG 949 (Aftercare with CC/MCC, relative weight 1.123) and DRG 950 (Aftercare without CC/MCC, relative weight 0.7664), in MDC 23 (Factors Influencing Health Status and Other Contacts with Health Services), as a principal or secondary diagnosis. The DRG a claim lands in depends on the principal diagnosis, procedures and any CC/MCC secondary diagnoses.
It is exempt from present-on-admission (POA) reporting, so no POA indicator is required.
It was added in FY2025, effective October 1, 2024.
7th character
Dsubsequent encounter
Other encounter types for T45.AX4:
Notes that apply from higher levels
Instructions written at a parent level also apply to T45.AX4D.
› From T45.A Poisoning by, adverse effect of and underdosing of immune checkpoint inhibitors and immunostimulant drugs
- poisoning by, adverse effect of and underdosing of antineoplastic and immunosuppressive drug (T45.1)
Broader instructions also apply from T36-T50 Poisoning by, adverse effects of and underdosing of drugs, medicaments and biological substances and Chapter 19: Injury, poisoning and certain other consequences of external causes.
MS-DRG v44.0 grouping
All DRGs →Inpatient MS-DRGs this diagnosis can group to, as the principal or a secondary diagnosis, depending on the rest of the claim.
MDC 23 · Factors Influencing Health Status and Other Contacts with Health Services
Code history
- 2016
- 2017
- 2018
- 2019
- 2020
- 2021
- 2022
- 2023
- 2024
- 2025
- 2026
- 2027
- FY2025 (effective 10/1/2024): Added
- No changes since FY2025.
Common questions about T45.AX4D
Is T45.AX4D billable?
- Yes. T45.AX4D is a billable/specific ICD-10-CM code valid for FY2027 (October 1, 2026 – September 30, 2027).
What does the "D" at the end of T45.AX4D mean?
- It is the 7th character for subsequent encounter. Per the official guidelines, use it for encounters after active treatment, while the patient is healing or recovering.
Can T45.AX4D be used as a principal diagnosis?
- Yes. The Medicare Code Editor doesn't restrict T45.AX4D as a principal diagnosis.
Is T45.AX4D a CC or MCC?
- No. T45.AX4D is neither a CC nor an MCC under MS-DRG v44.0.
What DRG does T45.AX4D group to?
- T45.AX4D is used in the MS-DRG v44.0 logic for MS-DRG 949 (Aftercare with CC/MCC) and MS-DRG 950 (Aftercare without CC/MCC). Which one applies depends on whether it is the principal diagnosis and on the rest of the claim.